Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma

Annals of Oncology : Official Journal of the European Society for Medical Oncology
H IzzedineBernard Escudier

Abstract

To examine the association between hypertension (HTN), angiotensin system inhibitors (ASI) use and survival outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib (SU). We retrospectively reviewed all patients with mRCC who received SU as first-line treatment in Gustave Roussy from April 2004 to November 2013. The HTN (either pre-existing or secondary to SU), use of ASI (either before or during SU) were analysed. Overall survival (OS) and progression-free survival (PFS) of different exposures were compared with log-rank test. The associations between exposures and survival outcomes were estimated with hazard ratios (HRs) and 95% confidence interval (CI) through a multivariable Cox model adjusted for age, gender, International mRCC Database Consortium risk group and histology. Among 213 patients with a 3.6-year median follow-up, 134 were hypertensive and 105 were ASI users with a significant association between the two exposures (P < 0.0001). Hypertensive patients have longer OS (median: 41.6 versus 16.4 months, P < 0.0001) and longer PFS (median: 12.9 versus 5.6 months, P < 0.0001) than non-hypertensive patients (n = 79). ASI users (n = 105) had more HTN_PRE compared with those (n = 108) who did...Continue Reading

References

Mar 7, 2003·American Journal of Physiology. Gastrointestinal and Liver Physiology·Terence ChiuEnrique Rozengurt
Aug 24, 2004·Current Vascular Pharmacology·Elizabeth EscobarJulio Sotelo
Aug 17, 2005·Current Cancer Drug Targets·Hiroji UemuraYoshinobu Kubota
May 6, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michio KosugiMasaru Murai
Oct 18, 2006·The Prostate·Takeo KosakaMasamichi Hayakawa
Jan 12, 2007·The New England Journal of Medicine·Robert J MotzerRobert A Figlin
Jan 12, 2007·The New England Journal of Medicine·Bernard EscudierUNKNOWN TARGET Study Group
Feb 24, 2007·Laboratory Investigation; a Journal of Technical Methods and Pathology·Nozomi ImaiSatoshi Umemura
May 12, 2007·European Urology·Paul C M S Verhagen
Jul 25, 2008·The New England Journal of Medicine·Josep M LlovetUNKNOWN SHARP Investigators Study Group
Dec 5, 2008·The New England Journal of Medicine·Giancarlo Spinzi, Silvia Paggi
Feb 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean-Charles SoriaHassane Izzedine
May 8, 2010·Nature Reviews. Urology·Wong-Ho ChowSusan S Devesa
Mar 26, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D J StoreyM Sharpe
May 24, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Daniel KeizmanMichael A Carducci
Jun 7, 2011·Biochemical and Biophysical Research Communications·Masaya KubotaHisataka Moriwaki
Nov 20, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B EscudierUNKNOWN ESMO Guidelines Working Group
Jan 17, 2014·Journal of the National Cancer Institute·George A MakarYu-Xiao Yang
Mar 14, 2014·The Journal of Clinical Hypertension·Yan LiBenkang Shi

❮ Previous
Next ❯

Citations

May 5, 2016·Expert Opinion on Drug Safety·Lisa DerosaBernard Escudier
Aug 5, 2016·British Journal of Cancer·Basma Greef, Tim Eisen
Aug 11, 2017·International Journal of Molecular Sciences·Mathias Alrø Fichtner BendtsenMarcus Krüger
Apr 7, 2017·American Journal of Physiology. Renal Physiology·Roman Shingarev, Edgar A Jaimes
Dec 22, 2017·Future Oncology·Manuela SchmidingerSylvie Négrier
May 1, 2018·Current Treatment Options in Cardiovascular Medicine·Inbar Agmon Nardi, Zaza Iakobishvili
Oct 6, 2017·Science Translational Medicine·Matthias Pinter, Rakesh K Jain
Dec 1, 2018·American Journal of Physiology. Heart and Circulatory Physiology·Viktoriya MozolevskaDavinder S Jassal
Apr 9, 2019·International Journal of Urology : Official Journal of the Japanese Urological Association·Jun TeishimaAkio Matsubara
Dec 12, 2017·International Journal of Cancer. Journal International Du Cancer·Madhur NayanUNKNOWN Canadian Drug Safety and Effectiveness Research Network (CDSERN)
Jan 10, 2019·Journal of Hypertension·Vasiliki KatsiDimitrios Tousoulis
Jan 15, 2016·Medicine·Giuseppe Di LorenzoCarlo Buonerba
May 1, 2018·Journal of Cardiovascular Pharmacology and Therapeutics·Cody N JusticeSakima A Smith
Feb 14, 2019·F1000Research·Timothy M Markman, Maurie Markman
Jan 31, 2020·Frontiers in Cardiovascular Medicine·Sherry-Ann Brown
Nov 23, 2017·United European Gastroenterology Journal·Matthias PinterWolfgang Sieghart
Jun 23, 2018·Current Oncology Reports·Megha AgarwalGeorge D Mitchell
Feb 13, 2018·Therapeutic Advances in Medical Oncology·Arduino A MangoniMichael J Sorich
Oct 2, 2020·Cancers·Fabian Bernhard Pallasch, Udo Schumacher
Sep 2, 2019·Heart Failure Clinics·Lauren J HassenRagavendra R Baliga
Feb 14, 2021·Diagnostics·Jon Danel Solano-IturriGorka Larrinaga

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.